✦ LIBER ✦

PCV73 ANALYSIS OF COST AND EFFECTIVENESS DATA USING RANDOM PERMUTATION METHODS

✍ Scribed by P Kolm

Book ID: 119594584
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 86 KB
Volume: 9
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)63688-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Confounding and missing data in cost-eff

Confounding and missing data in cost-effectiveness analysis: comparing different methods

✍ Tommi Härkänen, Timo Maljanen, Olavi Lindfors, Esa Virtala… 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 313 KB

PCV33: COST-EFFECTIVENESS ANALYSIS OF SI

PCV33: COST-EFFECTIVENESS ANALYSIS OF SIMVASTATIN AND LOVASTATIN/EXTENDED-RELEASE NIACIN TO ACHIEVE LDLAND HDL GOAL USING NHANES DATA

✍ EP Armstrong; WM Zachry III; DC Malone 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

A comparison of random field theory and

A comparison of random field theory and permutation methods for the statistical analysis of MEG data

✍ Dimitrios Pantazis; Thomas E. Nichols; Sylvain Baillet; Richard M. Leahy 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 676 KB

PCV38 COST-EFFECTIVENESS OF ANGIOTENSIN

PCV38 COST-EFFECTIVENESS OF ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTS WITH HYPERTENSION: A COMPARATIVE ANALYSIS USING CLINICAL TRIAL AND OBSERVATIONAL DATA

✍ C Boersma; AA Voors; PB Van den Berg; ST Visser; LT De Jong-van den Berg; MJ Pos 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Cost effectiveness of palivizumab in Spa

Cost effectiveness of palivizumab in Spain: an analysis using observational data

✍ Mark J. Nuijten; Wolfgang Wittenberg 📂 Article 📅 2009 🏛 Springer 🌐 French ⚖ 340 KB

Regression methods for covariate adjustm

Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data

✍ Andrew R. Willan; Andrew H. Briggs; Jeffrey S. Hoch 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB

## Abstract The current interest in undertaking cost‐effectiveness analyses alongside clinical trials has lead to the increasing availability of patient‐level data on both the costs and effectiveness of intervention. In a recent paper, we show how cost‐effectiveness analysis can be undertaken in a